PAC-Man Strategy

The PAC-Man strategy is a takeover defense in which a target company threatened with a hostile acquisition responds by launching a competing bid to acquire the hostile bidder. The target becomes the aggressor, “eating” the bidder in a reversal of roles. The strategy is named after the arcade game Pac-Man, in which the protagonist pursues and consumes ghosts. Success requires the target to have sufficient financial capacity and is rare because most targets are smaller than their bidders.

How PAC-Man works

A hostile bidder (Company A) launches a public takeover offer for the target (Company B), usually at a premium price that bypasses the target’s board. In classic hostile bidding, the bidder launches a tender offer directly to shareholders, promising to buy their shares at a fixed price (say, $25 per share) if enough shares are tendered (usually requiring >50% of outstanding shares).

The target’s board rejects the offer as undervaluing the company. Rather than deploy purely defensive tactics (poison pills, white knights, staggered boards), the target can reverse the tables: Company B launches its own tender offer for Company A, promising shareholders of Company A a premium price to tender their shares. Now both companies are bidding for each other.

The strategy hinges on a critical asymmetry: Company A’s shareholders are often more liquid and price-sensitive than Company B’s shareholders. If Company B can quickly mobilize capital (via stock issuance, debt, or asset sales) and make a credible, high-price offer for Company A, Company A’s shareholders may abandon Company A’s original bid and instead tender to Company B. The bidder finds itself in the unenviable position of being acquired by its target.

Strategic logic and financing

For PAC-Man to work, the target must credibly demonstrate financing capacity. Options include:

• Stock-based offer: Company B issues new shares and offers them to Company A shareholders. If Company B’s stock is highly valued (relative to Company A), this is effective. But issuing massive new shares dilutes existing shareholders and may depress stock price.
• Debt financing: Company B borrows money to fund the counterbid. This works if the target has balance-sheet capacity, but taking on large debt increases risk and may anger lenders and rating agencies.
• Asset sales: Company B divests business units to raise cash quickly. This is disruptive but proves seriousness.
• Hybrid (debt + stock + cash): Most PAC-Man offers bundle these, using the most credible financing mix available.

The credibility of financing is paramount. If shareholders believe Company B’s offer is not financeable, they will ignore it and hold out for Company A’s bid (or demand a higher price from both bidders).

Famous example: Bendix vs. Martin Marietta (1982)

The most celebrated PAC-Man battle involved Bendix Corporation (a diversified industrial company) bidding for Martin Marietta (aerospace and defense contractor), both headquartered in Maryland.

In 1982, Bendix launched a hostile tender offer for Martin Marietta at $43 per share (a 30% premium). Martin Marietta’s CEO, Thomas Pownall, was furious and swiftly launched a counter-bid for Bendix at $75 per share, a stunning 43% premium over Bendix’s trading price. The counter-bid was financed via debt and asset sales; Martin Marietta pledged to sell off Bendix divisions post-acquisition to repay debt.

Both companies’ shareholders faced a choice: the Bendix shareholders could take Martin Marietta’s $75-per-share offer, or hold out for Bendix to acquire Martin Marietta. The bidding escalated; eventually, Allied Corporation (a chemical company) intervened as a white knight, acquiring Bendix and backing away from the Martin Marietta bid. Martin Marietta succeeded in staying independent.

The battle was fierce, costly (legal and financial fees), and ultimately resolved via a third party. But it demonstrated that a credible counter-bid could shift power dynamics and force a compromise or negotiated settlement.

Why PAC-Man is rare

Despite its theoretical appeal, PAC-Man is uncommon because:

1. Size mismatch: Hostile bidders are typically larger (better access to capital) than targets. A smaller target launching a counter-bid for a larger bidder strains credibility. How can Company B (market cap $10B) credibly bid for Company A (market cap $20B) with limited float and debt capacity?

2. Financing constraints: Raising capital quickly at a high price is difficult. New debt increases leverage; new equity dilutes shareholders; asset sales take time and distract management. By the time the target has mobilized capital, the bidder may have already secured enough shares.

3. Regulatory risk: A successful PAC-Man requires the combined entity to pass antitrust review. If the combined company (post-PAC-Man) would be a monopolist or have anticompetitive effects, regulators may block it. This regulatory uncertainty weakens the target’s credibility.

4. Valuation volatility: If the stock market declines sharply during a bidding war, both offers become less attractive, and shareholders may reject both bids, demanding a higher price from either party. Volatility works against aggressive bidding.

5. Shareholder resistance: Shareholders of the target may prefer a cash exit (bidder’s offer) over a stock-based counter-bid with execution risk.

PAC-Man as a negotiating tactic

Because outright success is rare, targets often use PAC-Man threats as leverage. A credible counter-bid threat signals to the bidder: “We can fight you, and it will be costly and uncertain. Let’s negotiate a higher price for the target instead of both of us spending millions on a bidding war.”

This negotiating function is arguably PAC-Man’s most valuable use: the target demonstrates seriousness and financial capacity, forcing the bidder to either raise its offer, withdraw, or agree to negotiate with the target’s board for a friendly merger of equals.

Modern context

In the 2010s–2020s, PAC-Man has seen limited use. Instead, targets rely on poison pills (shareholder rights plans), engaging white knights, or strategic board changes (replacing CEO, adding activist directors) to negotiate higher prices. The fixed-price tender offer format has also evolved: modern hostile bids often come with no financing condition, forcing the bidder to prove immediately that it can pay.

That said, the strategic principle—that a target can flip the script and threaten the bidder—remains powerful. In the 2022 Twitter-Elon Musk saga, Twitter’s “poison pill” (a rights plan that would have diluted any acquirer’s stake) was a modern variant of the idea that the target can raise the bidder’s cost.